Abstract
Coccidioidal meningitis is a lethal disease, and current therapy is not curative or is burdened with serious toxicities and logistic difficulties. In a patient with refractory disease, continuous infusion amphotericin B therapy was given via a programmable implanted pump into the cisternal subarachnoid space. The patient progressively responded, evidenced clinically and by laboratory studies. Drug delivery issues were addressed during this course that could guide future use of this modality, which is a promising novel avenue of therapy for chronic meningitis.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amphotericin B* / administration & dosage
-
Amphotericin B* / cerebrospinal fluid
-
Amphotericin B* / therapeutic use
-
Antifungal Agents* / administration & dosage
-
Antifungal Agents* / cerebrospinal fluid
-
Antifungal Agents* / therapeutic use
-
Coccidioidomycosis / cerebrospinal fluid
-
Coccidioidomycosis / drug therapy
-
Humans
-
Infusion Pumps, Implantable*
-
Injections, Spinal
-
Male
-
Meningitis, Fungal / cerebrospinal fluid
-
Meningitis, Fungal / drug therapy
-
Young Adult
Substances
-
Antifungal Agents
-
Amphotericin B